Complication During VinV Procedure

Yohei Ohno, MD, PhD, FESC

Department of Cardiology, Tokai University School of Medicine



Clinical Case

- √ 65 years old, male
- √ Hypertension
- ✓ Ex smoker
- ✓ Dyslipidemia
- ✓ Peripheral artery disease
- √ Chronic kidney disease sCr 1.8 mg/dl, eGFR 43 ml/min

Clinical Case

- ✓ 1997
 SAVR for severe AS (mechanical prosthesis)
 Aorto-femoral & femoral-femoral by-pass for right and left CIA occlusion
- √ 1998
 Prosthetic valve thrombosis → re-do with a St. Jude Toronto Stentless 21
- ✓ 2010

 Hospitalizations for endocarditis → prosthetic valve degeneration and severe AR (Diastolic BP: 35 mmHg)
- ✓ 2011
 Septic cardioembolic stroke with residual hemiparesis and dysarthria
- ✓ 2013
 Dyspnea at rest (NYHA Class IV)

A touching dilemma A man trapped in his own body

- √ Hemiparesis Weel chair
- ✓ Dysarthria
- ✓ Dysphagia
- ✓ Needing 24/7 assistance
- ✓ Aware, asking for therapy



Baseline Imaging

Transthoracic echocardiography:

- LVEF 55%
- LVEDD: 65 mm
- Prosthetic aortic valve degeneration with severe AR
- Moderate TR (sPAP 50 mmHg)

Coronary angiogram:

No coronary artery disease (left dominance)

• MSCT:


- annulus measurements
- coronary ostia height
- peripheral access evaluation

Crossroad # 1 To treat or not to treat

- ✓ Medical therapy (too frail to treat?)
- ✓ Re-re-do
- ✓ Transcatheter ViV




MSCT Measurements: annulus





MSCT measurements: Coronary height




Length: 0.695 cm (16.282 pix)

RCA take-off 12.9 mm

Low LM take-off 6.9 mm

MSCT measurements: peripheral access

- ✓ Left subclavian artery significantly diseased
- ✓ Tortuous right subclavian artery
- ✓ Right aorto-femoral by-pass
- ✓ Femoral-Femoral by-pass





Risk Assessment & Heart Team Discussion

- EuroScore I:
 - Logistic 34.78%
 - Additive 13
- EuroScore II: 16.06%


- STS:
 - Mortality 10.7%
 - Morbidity or Mortality 58.6%



TAVR (ViV)



Toronto Stentless characteristics







- ✓ Porcine valve
- √ OD 21
- ✓ ID 19

Crossroad # 2

√ Which THV?

√ Which access route?


COREVALVE for following reasons

- √ Convex/concave frame shape
- ✓ Pure AR with minimum calc
- ✓ Direct aortic access



TAVR: Corevalve Revalving System


- 26-mm CRS
- Transaortic route




	23mm	26mm	29mm	31mm
Annulus Diameter [mm]	D≥18	D≥20	D≥23	D≥26
	D≤20	D≤23	D≤27	D≤29
Annulus Area [cm2]	A≥2,54 A≤3,14	A≥3,14 A≤4,15	A≥4,15 A≤5,72	A≥5,31 A≤6,60
Annulu Perimeters [cm]	P≥5,65 P≤6,28	P≥6,28 P≤7,22	P≥7,22 P≤8,48	P≥8,16 P≤9,11




CRS 26 mm Implantation





CRS 26 mm Implantation



After ViV

- ✓ No AR, very stable patient
- ✓BP: 140/80 mmHg
- ✓ No rythm disturbances




15 min later

- ✓ Drop of BP from 140/80 to 70/30 mmHg
- √ Fall in LVEF
- ✓ Bradycardia < 35 bpm
 </p>
- ✓ TPM started to pace at 70 bpm
- ✓ Start infusion of plasma expander
- ✓ Start administration of inotropes


What could be the cause?

- √ Cardiac tamponade
- ✓ Annular rupture
- √ Conduction disturbances
- √ Valve pop-up
- ✓ Coronary obstruction
- √ Stroke
- √ Bleeding






Coronary Angiogram



5 min later






Crossroad # 3 How should we treat?

- ✓ LM wiring and stenting
- √ Valve snaring
- ✓ Balloon pop-up
- ✓ Hemodynamic support (Impella ± ECMO)



Pop-up attempt

- ✓ Pop-up attempt with a Balloon 28/40 mm
- ✓ Cardiac arrest
- ✓ CPR started



Take Home Messages

- ✓ It is mandatory to have the precise information of the bioprosthetic valve (manufacturer, model and size) in ViV procedure
- ✓ Preoperative MSCT is mandatory to evaluate the risk of coronary obstruction
- ✓ Consider late nitinol expansion for self-expandable device
- ✓ Even after careful planning of the procedure, complications still may occur
- ✓ Pre-emptive coronary wiring and stent delivery could save life for very high risk case of coronary obstruction

Thank you for your kind attention